290 likes | 593 Views
Acute Myocardial Infarction (MI) ___________________________. Leading cause of death of men
E N D
1. Alteration in Cardiac Perfusion & Output Part 2 Rose Bianchi, RN, DNSc.
Copyright 2011 and 2008
3. Types of MI___________________________ Non-Q wave (subendocardial)
Q-Wave (Transmural)
4. Pathophysiology of MI___________________________ Lack of Blood Supply & O2 to the Myocardium
|
Anaerobic Metabolism
|
Lactic Acid Production
|
Acidosis
|
Conduction System Disorders
Dysrhythmias
Reduced Cardiac Contractility& Cardiac Output
5. Sites of MI___________________________ Anterior Wall of Left Ventricle (L.V.)
a. Thrombus in Descending Branch of Left Coronary Artery (C.A.)
2. Posterior Wall Of LV
a. Thrombus in Right C.A. or
b. Circumflex Branch of Left C.A.
3. Inferior (Diaphragmatic) Surface of the Heart
a. Thrombus in Right C.A.
6. Sites of MI___________________________
4. Lateral
5. Septal
7. Clinical Manifestations of MI___________________________ Chest Pain Unrelieved by NTG &/or Rest
may radiate to neck, jaw , shoulder , back, or down left arm
Women often present with just SOB, fatigue, dizziness , indigestion , &/or back pain
Nausea, vomiting, indigestion,
Sympathetic Nervous System Stimulation diaphoresis, vasoconstriction
Fever up to 100.4
Elevated BP & HR first , later Decreased BP due to low C.O.
Edema peripheral &/or pulmonary
Abnormal Heart Sounds S3 or S4
8. EKG Changes with MI___________________________ Ischemia causes ST segment elevation
Peaked or inverted T wave
9. Lab Tests For a Client with a MI___________________________ Elevated Lab Tests
1. Serum Creatine Kinase (CPK MB)
Normal Value: 21 232 u/l
Elevates in 3 6 hrs. After a MI,
Peaks in 12 18 hrs.,
Returns to normal in 3 4 days
2. Troponin I Normal < 0.5 ng/ml
Borderline Result 0.5 1.99 ng/ml
May Indicate MI - >2.00
Rises fast, Peaks in 24 48 hrs.
10. Elevated Lab Tests in MI___________________________ Serum Aspartate Aminotransferase (AST)
Elevates several hours after MI,
Peaks in 12 18 hrs.
Returns to Normal in 3 4 days
Serum Lactate Dehydrogenase (LDH) M1 Isoenzyme
Elevates 14 24 hrs.after MI
Peaks in 48 72 hrs.
Returns to normal in 7 14 days
11. Elevated Lab Tests in MI___________________________ C-Reactive Protein
Normal Value < 1.0 mg/dl
Leukocytosis Elevated WBC
10,000 20,000 per mm3,
Occurs Day 2
Serum Erythrocyte Sedimentation Rate
12. Overhead Projector Slides of Examples of Client Lab Values _____________________________________
13. Treatment for Unstable Angina/Non-ST-Segment MI (NSTEMI)__________________________________________ I. Acute Intensive Therapy
a. Nitroglycerin
b. Low Molecular Weight Heparin
c. Clopidogrel (Plavix)
d. Glycoprotein IIb Inhibitors- Eptifibatide (Integrellin)
II. Coronary Angioplasty
a. Percutaneous Coronary Intervention (PCI)
14. ST- Segment Elevation MI (STEMI)___________________________________ Immediate Reperfusion Therapy
a. Percutaneous Coronary Intervention (PCI)
b. Fibrinolytic Therapy
c. Emergent CABG Surgery
15. DiagnosticTests and Procedures for the Client with MI _____________________________________
Radionuclide Imaging
Magnetic Resonance Imaging (MRI)
Echocardiography
Cardiac Catheterization
Angioplasty
Coronary Artery Bypass Grafting (CABG)
16. Goals of Care for the Client with an Acute MI _____________________________________
Treat MI & its symptoms
Prevent Complications & Another MI
Educate & Rehabilitate the Client
17. ICU Interventions___________________________ Arterial Lines
Swan Ganz Catheter Monitoring
Pain Management
O2 Therapy
EKG Monitoring
18. Thrombolytic Therapy for the Client with MI __________________________________________1. Start within 3 6 hours of start of the
chest pain
2. Drugs Used
a. t-PA (Tissue Plasmingen Activator)
b. Streptokinase or
c. Urokinase
3. Complications bleeding, stroke, allergic reactions
20. Drug Therapy for the Client with a MI _____________________________________
Nitroglycerin
a. Sublingual Tablets
b. IV NTG (Tridil) reduces pain, preload & afterload, & increases O2 supply
1. Starting dose 0.25 0.5 ug/kg/min.
2. Usual Dose 1 3 ug/kg/min.
3. Titrate to reduce pain & keep
SBP >90 100 mm Hg
21. Drug Therapy forthe Client with a MI _____________________________________
2. Morphine IVP
a. Main Action: to reduce chest pain
b. By reducing chest pain, get secondary
effects reduction in cardiac
workload by lowering myocardial
O2 consumption, & reducing
contractility, BP, & HR
3. Beta Adrenergic Blockers
a. Action: increases O2 supply to the heart
& reduces myocardial demand by
decreasing HR
22. Drug Therapy forthe Client with MI _____________________________________
5. Calcium Channel Blockers
a. Action: diminish calcium influx into cells,
cause dilation of coronary arteries & arterioles,
inhibit coronary artery spasm
6. Stool Softeners ( Docusate Sodium, Colace)
a. Action: prevent straining, which causes
vagal stimulation ? bradycardia &
dysrhythmias,
Also, after straining there is increased
venous return to the heart loading
a weakened heart
23. Drug Therapy for the Client with MI _____________________________________
7. Heparin Therapy
a. Action: enhances the inhibitory actions of
antithrombin III on several factors
essential to normal blood clotting,
blocks conversion of prothrombin to
thrombin & fibrinogen to fibrin,
inhibits formation of new clots
24. Cardiac Rehabilitation Goals ___________________________ 1. Develop progressive physical activity
Educate about the cause, treatment, &
prevention of CAD
3. Reduce risk factors
4. Accept limitations
Make lifestyle changes
Adjust to occupational changes
25. Discussion of Cardiac Rehabilitation Process ____________________________________
26. Complications of MI___________________________ Dysrhythmias
Cardiogenic Shock
Left Sided Heart Failure & Pulmonary Edema
Pulmonary Embolism
Recurrent MI
Myocardial Necrosis
Pericarditis
Papillary Muscle Dysfunction
27. Cardiogenic Shock___________________________ Causes:
1. Decreased myocardial contraction
& diminished cardiac output (C. O.)
2. Undetected dysrhythmias
3. Sepsis
Signs & Symptoms: low SBP, tachycardia,
diaphoresis, restlessness, AMS,
cold, clammy , gray skin
Prevention: Relieve pain, IV fluids
28. Treatment of Cardiogenic Shock___________________________
1. Vasopressors - to raise BP by increasing
peripheral resistance
a. Norepinephrine
b. Dopamine 2 5 mcg/kg/min.
IV Drip
c. Dobutamine 2.5 10.0 mcg/kg/min. IV Drip
d. Metaraminol
29. Treatment of Cardiogenic Shock___________________________ 2. Vasodilators to promote better blood flow
in the microcirculation of
the heart, to decrease
preload & afterload
a. Nitroprusside 0.5 8.0 mcg/kg/min. IV Drip
30. Treatment for Cardiogenic Shock___________________________ 3. Positive Inotropic Agents
To increase cardiac (ventricular)
contractility & C.O.
To improve tissue perfusion
a. Dobutamine
b. Epinephrine
c. Isoproterenol
0.5 5.0 mcg/kg/min. IV Drip
4. O2 Therapy
5. Antiarrhythmic Agents prn
6. Continuous Arterial Monitoring
31. Treatment of Cardiogenic Shock___________________________ 7. Swan Ganz Monitoring
8. Diuretics for volume overload
9. Intra-aortic Balloon Pump
10. Emergency Surgery Angioplasty or CABG
32. Nursing Diagnoses for the Client with a MI _____________________________________
Alteration in Comfort (Chest Pain) R/T Myocardial Ischemia from Coronary Artery Occlusion & Myocardial Necrosis
Dysrhythmias R/T Electrical Instability or Irritability 2ary to Ischemia or Infarcted Tissue
Decreased Cardiac Output R/T Negative Inotropic Changes in the Myocardium 2ary to Myocardial Ischemia , Injury, or Infarction
Impaired Gas Exchange R/T Decreased Cardiac Output
Anxiety or Fear R/T Change in Health Status, Hospitalization & Life threatening Illness
33. Nursing Diagnoses forthe Client with a MI _____________________________________
6. Alteration in Health Maintenance R/T MI and necessary Lifestyle Changes
7. Activity Intolerance R/T Imbalance of Oxygen Supply & Demand
34. Invasive Procedures to TreatC.A. Occlusion _____________________________________
Percutaneuos Transluminal Coronary Angioplasty (PTCA)
a. Complications: dissection of C.A.,
infarction, abrupt C.A. closure
Atherectomy
a. Complications: thrombosis, restenosis
PTCA with Stent Placement
a. Post Procedure Medications Integrillin
GTT first, then start ASA &Plavix
b. Complications: hemorrhage, vascular
injury, stent thrombosis, MI,
coronary artery spasm
35. Invasive Procedures to Treat C.A. Occlusion _____________________________________
4. Laser Angioplasty
a. Complications: C.A. dissection,
acute occlusion, perforation, embolism
36. Surgical Treatment ofIschemic Heart Disease _____________________________________
Minimally Invasive Coronary Artery Bypass Grafting (MIDCABG)
CABG
a. Vessels Used: Saphenous Vein,
Left Internal Mammary Vein,
or Radial Artery
37. Heart Valve Replacement Surgery _____________________________________
a. Types of Valves
1. Artificial or Mechanical
2. Human Valve
38. Preoperative Care for Cardiac Surgery _____________________________________
See Syllabus Unit
39. Postoperative Care for the Client Undergoing Cardiac Surgery _____________________________________
Assessment
BP via arterial line
Radial & Apical Pulses
Temperature
Respiratory Rate & O2 Saturation
Chest Tubes
40. Cardiac Surgery Postoperative Nursing Problems _____________________________________
Fluid Overload
Risk of Altered Renal Function
Electrolyte Imbalance
Altered LOC
Risk for Decreased Cardiac Output
Risk for Ineffective Airway Clearance
Hemorrhage
Alteration in Comfort
41. Cardiac Surgery Postoperative Nursing Problems _____________________________________
9. Risk for Paralytic Ileus
10. Impaired Physical Mobility
11. Risk for Infection